To see whether LAL plays a role in regulating MSCs′ effect on tumor progression, the B16 melanoma cell model was used for subcutaneous and intravenous co-injection with bone marrow MSCs in both syngeneic C57BL/6 and allogeneic FVB/N mouse models. The gene discussed is LIPA; the disease is melanoma.